Methods for treating hypothyroidism
First Claim
Patent Images
1. A method for treating hypothyroidism in an adult subject having hypothyroidism, comprising the long-term administration to the adult subject of T3 at a dose of 0.005-0.03 μ
- g/kg body weight/hour/day effective to treat hypothyroidism in the subject.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods for treatment of hypothyroidism in an adult comprising the long-term administration of T3 at a dose of 0.005-0.03 μg/kg body weight/hour/day or a at daily dose of 5-25 μg T3 in a sustained-release formulation, in the absence of administration of a therapeutic dose of T4.
-
Citations
52 Claims
-
1. A method for treating hypothyroidism in an adult subject having hypothyroidism, comprising the long-term administration to the adult subject of T3 at a dose of 0.005-0.03 μ
- g/kg body weight/hour/day effective to treat hypothyroidism in the subject.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 38, 40, 44, 45)
-
19. A formulation wherein T3 is released at a dose of 0.005-0.03 μ
- g/kg body weight/hour/day.
- View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27)
-
28. A method for treating hypothyroidism in an adult subject having hypothyroidism, comprising the long-term administration to the adult subject of a daily dose of 5-25 μ
- g T3 in a sustained-release formulation, in the absence of administration of a therapeutic dose of T4, effective to treat hypothyroidism in the subject.
- View Dependent Claims (29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 46)
-
47. A sustained-release formulation comprising 5-25 μ
- g T3 in the absence of T4 as an active ingredient.
- View Dependent Claims (48, 49)
-
50. A sustained-release formulation comprising 2.5-12.5 μ
- g T3 in the absence of T4 as an active ingredient.
- View Dependent Claims (51, 52)
Specification